688065 凯赛生物
已收盘 07-15 15:00:00
资讯
新帖
简况
凯赛生物获得发明专利授权：“连续纤维增强生物基共聚酰胺管材及其制备方法和应用”
证券之星 · 07-15 03:27
凯赛生物获得发明专利授权：“连续纤维增强生物基共聚酰胺管材及其制备方法和应用”
凯赛生物及其子公司提起商业秘密侵权诉讼，索赔约9.67亿元
美股速递 · 07-14 18:33
凯赛生物及其子公司提起商业秘密侵权诉讼，索赔约9.67亿元
凯赛生物：提起专利侵权诉讼 索赔约9.67亿元
格隆汇 · 07-14 17:58
凯赛生物：提起专利侵权诉讼 索赔约9.67亿元
凯赛生物（688065）新增【减肥药】概念
证券之星 · 07-13 20:30
凯赛生物（688065）新增【减肥药】概念
凯赛生物：公司客户结构多元化，长链二元酸业务整体保持稳健发展
证券之星 · 07-13 15:33
凯赛生物：公司客户结构多元化，长链二元酸业务整体保持稳健发展
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
证券之星 · 07-09
凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中
凯赛生物：公司持续关注生物基航油等方向的技术动态与产业政策
证券之星 · 07-09
凯赛生物：公司持续关注生物基航油等方向的技术动态与产业政策
7月7日凯赛生物跌5.66%，科创新材料ETF博时基金重仓该股
证券之星 · 07-07
7月7日凯赛生物跌5.66%，科创新材料ETF博时基金重仓该股
每周股票复盘：凯赛生物（688065）2025年年度股东会决议公告
证券之星 · 06-28
每周股票复盘：凯赛生物（688065）2025年年度股东会决议公告
凯赛生物（688065）披露2025年年度股东会决议公告，6月25日股价下跌0.72%
证券之星 · 06-25
凯赛生物（688065）披露2025年年度股东会决议公告，6月25日股价下跌0.72%
股市必读：凯赛生物（688065）6月22日董秘有最新回复
证券之星 · 06-23
股市必读：凯赛生物（688065）6月22日董秘有最新回复
凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用
证券之星 · 06-22
凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用
凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证
证券之星 · 06-22
凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证
凯赛生物：股份回购需综合考虑资金安排、资本开支及监管要求等因素
证券之星 · 06-22
凯赛生物：股份回购需综合考虑资金安排、资本开支及监管要求等因素
凯赛生物：上述两个项目的产品定位与应用方向有所不同
证券之星 · 06-22
凯赛生物：上述两个项目的产品定位与应用方向有所不同
股市必读：凯赛生物（688065）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：凯赛生物（688065）6月18日董秘有最新回复
每周股票复盘：凯赛生物（688065）董事会秘书变更
证券之星 · 06-20
每周股票复盘：凯赛生物（688065）董事会秘书变更
凯赛生物（688065）披露关于变更持续督导保荐代表人的公告，6月18日股价上涨2.88%
证券之星 · 06-18
凯赛生物（688065）披露关于变更持续督导保荐代表人的公告，6月18日股价上涨2.88%
凯赛生物：秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向
证券之星 · 06-18
凯赛生物：秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向
凯赛生物（688065）披露董事会秘书变更公告，6月16日股价下跌3.05%
证券之星 · 06-16
凯赛生物（688065）披露董事会秘书变更公告，6月16日股价下跌3.05%
加载更多
公司概况
公司名称：
上海凯赛生物技术股份有限公司
所属行业：
化学纤维制造业
上市日期：
2020-08-12
主营业务：
上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。
发行价格：
133.45
{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":43.25,"timestamp":1784098800000,"preClose":42.93,"halted":0,"volume":5696952,"delay":0,"changeRate":0.0075,"floatShares":583000000,"shares":721000000,"eps":0.8173,"marketStatus":"已收盘","change":0.32,"latestTime":"07-15 15:00:00","open":42.94,"high":43.83,"low":42.1,"amount":246000000,"amplitude":0.0403,"askPrice":43.26,"askSize":11,"bidPrice":43.25,"bidSize":255,"shortable":0,"etf":0,"ttmEps":0.8173,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784165400000},"marketStatusCode":5,"adr":0,"adjPreClose":42.93,"symbolType":"stock_kcb","openAndCloseTimeList":[[1784079000000,1784086200000],[1784091600000,1784098800000]],"highLimit":47.22,"lowLimit":38.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":721289794,"isCdr":false,"pbRate":1.75,"roa":"--","peRate":52.918145,"roe":"0.93%","epsLYR":0.82,"committee":0.350195,"marketValue":31196000000,"turnoverRate":0.0098,"status":0,"afterMarket":{"amount":0,"volume":0,"close":43.25,"buyVolume":1820,"sellVolume":0,"time":1784100837746,"indexStatus":"已收盘 07-15 15:30:00","preClose":42.93},"floatMarketCap":25231000000},"requestUrl":"/m/hq/s/688065","defaultTab":"news","newsList":[{"id":"2651865954","title":"凯赛生物获得发明专利授权：“连续纤维增强生物基共聚酰胺管材及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651865954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651865954?lang=zh_cn&edition=full","pubTime":"2026-07-15 03:27","pubTimestamp":1784057222,"startTime":"0","endTime":"0","summary":"今年以来凯赛生物新获得专利授权35个，较去年同期增加了12.9%。通过天眼查大数据分析，上海凯赛生物技术股份有限公司共对外投资了15家企业，参与招投标项目8次；财产线索方面有商标信息158条，专利信息807条，著作权信息11条；此外企业还拥有行政许可9个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500004882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144499362","title":"凯赛生物及其子公司提起商业秘密侵权诉讼，索赔约9.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144499362","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144499362?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:33","pubTimestamp":1784025196,"startTime":"0","endTime":"0","summary":"凯赛生物及其一家子公司已向法院提起诉讼，指控其商业秘密遭到侵犯，并就此寻求约9.67亿元人民币的损害赔偿。该公司表示，此次法律行动旨在保护其核心技术资产与知识产权，维护公司的合法权益与市场竞争力。诉讼的具体细节，包括被告方身份及所涉技术领域，尚未在公告中完全披露。这一索赔金额反映了公司对相关技术商业价值的评估及其对潜在损失的估算。目前，案件已进入司法程序，后续进展有待进一步关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651171666","title":"凯赛生物：提起专利侵权诉讼 索赔约9.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651171666","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651171666?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:58","pubTimestamp":1784023095,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119771","title":"凯赛生物（688065）新增【减肥药】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651119771?lang=zh_cn&edition=full","pubTime":"2026-07-13 20:30","pubTimestamp":1783945821,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，7月13日凯赛生物新增概念。凯赛生物主营业务：以合成生物学等学科为基础,利用生物制造技术,从事新型生物基材料的研发、生产及销售。凯赛生物2026年一季报显示，一季度公司主营收入8.75亿元，同比上升12.73%；归母净利润1.66亿元，同比上升21.01%；扣非净利润1.48亿元，同比上升9.07%；负债率12.51%，投资收益-376.03万元，财务费用2650.62万元，毛利率36.04%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300036908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651789199","title":"凯赛生物：公司客户结构多元化，长链二元酸业务整体保持稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2651789199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651789199?lang=zh_cn&edition=full","pubTime":"2026-07-13 15:33","pubTimestamp":1783927987,"startTime":"0","endTime":"0","summary":"赢创聚酯全业务的关停，对凯赛的二元酸业务及其他生物基业务有哪些积极和消极影响？赢创是全球领先的特种化工企业，是公司在长链二元酸领域的下游客户之一。目前公司客户结构多元化，长链二元酸业务整体保持稳健发展。同时，公司目前有部分业务同赢创退出的业务处于相同赛道，有一定机会争取部分市场份额。公司将持续关注该事项进展，并根据实际情况积极应对。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300016465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944982","title":"凯赛生物：年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944982","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944982?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:33","pubTimestamp":1783582391,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：请问太原合成生物园的专用铁路是否已经动工？热电工程进展如何？污水处理项目进展如何？谢谢！凯赛生物回复：尊敬的投资者，您好。公司年产50万吨生物基戊二胺及年产90万吨生物基聚酰胺项目目前正在建设中。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900021828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944938","title":"凯赛生物：公司持续关注生物基航油等方向的技术动态与产业政策","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944938?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:33","pubTimestamp":1783582389,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物07月09日在投资者关系平台上答复投资者关心的问题。公司持续关注生物基航油等方向的技术动态与产业政策，对包括生物基航油在内的多种绿色能源与材料保持着密切的技术跟踪与探索，并会基于自身技术优势、市场需求变化以及国家产业政策的指引，审慎评估产业化布局与优先级。具体规划请以公司公开信息披露为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900021823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649988812","title":"7月7日凯赛生物跌5.66%，科创新材料ETF博时基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649988812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649988812?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:28","pubTimestamp":1783412914,"startTime":"0","endTime":"0","summary":"证券之星消息，7月7日凯赛生物跌5.66%，收盘报46.66元，换手率0.94%，成交量5.47万手，成交额2.61亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为博时基金的科创新材料ETF博时。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700027375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["588010","688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646318769","title":"每周股票复盘：凯赛生物（688065）2025年年度股东会决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2646318769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646318769?lang=zh_cn&edition=full","pubTime":"2026-06-28 01:44","pubTimestamp":1782582254,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，凯赛生物报收于47.62元，较上周的44.29元上涨7.52%。本周，凯赛生物6月23日盘中最高价报51.95元。本周关注点公司公告汇总：凯赛生物2025年年度股东会于2026年6月25日召开，所有议案均获通过。公司公告汇总上海市锦天城律师事务所就上海凯赛生物技术股份有限公司2025年年度股东会的召集程序、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果等事项出具法律意见书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646080962","title":"凯赛生物（688065）披露2025年年度股东会决议公告，6月25日股价下跌0.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646080962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646080962?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:28","pubTimestamp":1782397695,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘，凯赛生物报收于49.84元，较前一交易日下跌0.72%，最新总市值为359.49亿元。该股当日开盘50.15元，最高50.44元，最低48.94元，成交额达2.87亿元，换手率为0.99%。近日，凯赛生物发布《2025年年度股东会决议公告》。所有议案均获通过，无反对或否决情况。出席会议股东共256人，代表有表决权股份总数的59.61%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077113","title":"股市必读：凯赛生物（688065）6月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645077113?lang=zh_cn&edition=full","pubTime":"2026-06-23 04:01","pubTimestamp":1782158519,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，凯赛生物报收于50.7元，上涨14.47%，换手率2.78%，成交量16.22万手，成交额7.74亿元。董秘最新回复投资者： 你好，贵公司产品在人形机器人和其他机器人领域是否有应用？公司高度重视股东回报，并持续关注股价表现。股份回购需综合考虑资金安排、资本开支及监管要求等因素，如有相关计划，公司将严格按照规定履行信息披露义务。当日关注点交易信息汇总：6月22日主力资金净流入32.99万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300003883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044714","title":"凯赛生物：基于生物基热塑性复合材料可在机器人关节、骨架等部件应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645044714?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:37","pubTimestamp":1782113862,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，贵公司产品在人形机器人和其他机器人领域是否有应用？未来在机器人方向应用空间？谢谢凯赛生物回复：尊敬的投资者，您好。基于凯赛生物基热塑性复合材料的优异性能，可以在机器人的关节、骨架、外壳、电池壳体以及轴承等部件应用，为机器人带来高强度、轻量化、耐疲劳以及环保性等核心价值。目前公司产品已经给客户送样。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044241","title":"凯赛生物：生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645044241?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:36","pubTimestamp":1782113780,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在去年业绩说明会上提到“光伏边框”正在进行TUV认证，一年过去了，到现在这个认证进展到什么程度了？在今年的业绩说明会互动交流中，公司提到光伏边框正在进行示范项目的产能建设，能具体介绍下这个事的情况吗凯赛生物回复：尊敬的投资者，您好。公司生物基聚酰胺复合材料在光伏边框领域的应用在进行不同工艺的产品开发和测试验证，并计划联合战略合作方推进应用示范项目的产能建设。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645604478","title":"凯赛生物：股份回购需综合考虑资金安排、资本开支及监管要求等因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2645604478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645604478?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:36","pubTimestamp":1782113779,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价上市即巅峰，严重破发，为什么公司不大幅度回购以提振投资者信心。凯赛生物回复：尊敬的投资者，您好。公司高度重视股东回报，并持续关注股价表现。股份回购需综合考虑资金安排、资本开支及监管要求等因素，如有相关计划，公司将严格按照规定履行信息披露义务。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645044206","title":"凯赛生物：上述两个项目的产品定位与应用方向有所不同","url":"https://stock-news.laohu8.com/highlight/detail?id=2645044206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645044206?lang=zh_cn&edition=full","pubTime":"2026-06-22 15:36","pubTimestamp":1782113779,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司在2024年年报里就已提到乌苏年产2万吨长链聚酰胺已结项，但在2025年里一直没有产能和销售营收的贡献。想问，这个新建的长链尼龙和2023年结项的2万吨长链聚酰胺是相同的产品吗？公司基于产品特点和市场需求综合规划产品线布局，上述两个项目的产品定位与应用方向有所不同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200016576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645155390","title":"股市必读：凯赛生物（688065）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645155390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645155390?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:40","pubTimestamp":1782067220,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，凯赛生物报收于44.29元，上涨2.88%，换手率1.09%，成交量6.37万手，成交额2.83亿元。公司公告汇总关于变更持续督导保荐代表人的公告上海凯赛生物技术股份有限公司接到中信证券通知，原持续督导保荐代表人孟夏先生因工作安排不再负责公司持续督导工作；中信证券委派邵荣圣先生接替其职务，继续履行持续督导职责。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063106","title":"每周股票复盘：凯赛生物（688065）董事会秘书变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063106","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063106?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:15","pubTimestamp":1781892913,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，凯赛生物报收于44.29元，较上周的45.22元下跌2.06%。本周，凯赛生物6月15日盘中最高价报46.39元。本周关注点公司公告汇总：董事会秘书由臧慧卿变更为郑倩，臧慧卿仍任副董事长等职。同日，公司第三届董事会第十次会议审议通过聘任郑倩女士为新任董事会秘书，任期与第三届董事会一致。郑倩女士具备任职资格，已取得科创板董事会秘书资格证书。公司董事会对孟夏先生在持续督导期间的贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644084808","title":"凯赛生物（688065）披露关于变更持续督导保荐代表人的公告，6月18日股价上涨2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644084808","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644084808?lang=zh_cn&edition=full","pubTime":"2026-06-18 22:27","pubTimestamp":1781792835,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，凯赛生物报收于44.29元，较前一交易日上涨2.88%，最新总市值为319.46亿元。近日，上海凯赛生物技术股份有限公司披露《关于变更持续督导保荐代表人的公告》。公告显示，公司接到中信证券通知，原持续督导保荐代表人孟夏先生因工作安排不再负责公司持续督导工作；中信证券委派邵荣圣先生接替其职务，继续履行持续督导职责。公司董事会对孟夏先生在持续督导期间的贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800042572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644970226","title":"凯赛生物：秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2644970226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644970226?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:24","pubTimestamp":1781778251,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物(688065)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：您好：请问公司的万吨级的秸秆高值化利用项目进展如何？进入中试阶段了吗？转化率多高？谢谢！凯赛生物回复：尊敬的投资者，您好。秸秆高值化利用是公司非粮原料产业化研发和布局的重要方向，公司持续关注秸秆综合利用的技术和产业趋势，并正在考察合适的项目落地地点和商业可行性，相关工作正按计划推进。感谢您的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800032834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643763308","title":"凯赛生物（688065）披露董事会秘书变更公告，6月16日股价下跌3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763308","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643763308?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:16","pubTimestamp":1781619382,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，凯赛生物报收于43.51元，较前一交易日下跌3.05%，最新总市值为313.83亿元。该股当日开盘44.6元，最高44.75元，最低43.4元，成交额达2.19亿元，换手率为0.86%。近日，上海凯赛生物技术股份有限公司发布《关于董事会秘书变更的公告》。同日，公司第三届董事会第十次会议审议通过聘任郑倩女士为新任董事会秘书，任期与第三届董事会一致。郑倩女士具备任职资格，已取得科创板董事会秘书资格证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784136852296,"stockEarnings":[{"period":"1week","weight":-0.0474},{"period":"1month","weight":-0.0363},{"period":"3month","weight":-0.113},{"period":"6month","weight":-0.233},{"period":"1year","weight":-0.0728},{"period":"ytd","weight":-0.1315}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0345},{"period":"3month","weight":-0.0246},{"period":"6month","weight":-0.0357},{"period":"1year","weight":0.1286},{"period":"ytd","weight":-0.0033}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","boardName":"化学纤维制造业","stockholders":"18523人(较上一季度增加28.48%)","perCapita":"31494股","listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","registeredCapital":"72128万元","survey":" 上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。","listedPrice":133.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}